[ad_1]
The FDA has approved emergency use of the only drug Eli Lilly that contains anti-corona virus antibodies for the treatment of patients with mild or moderate COVID-19.
The Daily Mail newspaper said the drug will begin shipping immediately and will be assigned to states on a weekly basis based on case data provided to the HHS.
The US government has signed a $ 375 million contract with Lilly for 300,000 doses of the drug, which can purchase another 650,000 doses until the end of June.
Former President Trump had promised to make COVID-19 antibody treatments free for anyone who needs them, but it’s unclear how or if this is possible.
The newspaper said the U.S. Food and Drug Administration gave permission last night, Monday, for the emergency use of Eli Lilly’s experimental antibody treatment against Corona virus COVID-19, which was praised by the former president. Donald Trump and pledged to make it available for free to all Americans.
The US agency explained that its license for emergency use was based on clinical studies that showed that the treatment, called bamlanivimab, reduced the need for hospitalization or emergency room visits for high-risk COVID-19 patients. to develop the disease.
Early results indicate that it can help get rid of the coronavirus earlier and can reduce hospitalization for people with mild to moderate COVID-19.
And the U.S. Food and Drug Administration has approved its use in mild to moderate cases of COVID-19 in adults and children over the age of 12.
Leila said the drug will begin shipping immediately to the main distributor AmerisourceBergen.
Last month, the US government signed a $ 375 million deal with Lilly for 300,000 doses of the antibody drug to be distributed over the next two months of the EUA. The government will have the option to purchase another 650,000 doses until June 30.
The journal added that although Lilly did not specify the number of ready-made doses at the time, she had previously reported that 100,000 doses of her antibody drug could be provided within days of EUA’s emergency approval.
It confirmed that Bamlanivimab will be assigned weekly to the United States, depending on the number of confirmed cases recorded in the Department of Health and Human Services (HHS) data for each jurisdiction over the past seven days.
The newspaper added that two weeks ago, Lilly revealed that treating her with antibodies to the coronavirus almost completely reduces the viral load in patients with mild or moderate coronavirus to zero and reduces the risk of them being hospitalized.
The researchers found that patients with mild and moderate disease who were given a high dose of the LY-CoV555 antibody, also known as bamlanivimab, had 3.4 times lower viral loads than those who received a placebo.
Additionally, those who received any dose of LY-CoV555 were 4 times less likely to be hospitalized.
.
[ad_2]
Source link
